AiCuris was created in 2006 as a spin-out of Bayer’s anti-infective division and is backed by the ATHOS KG as lead investor and other private investors well known in Germany. We develop innovative drugs against severe and life-threatening infectious diseases. By targeting indications with high medical need, as well as preparing for pandemic and resistance emergencies, we focus on markets where no efficient solution is available and bring novel approaches into a long-underserved sector.


Delivering Anti-Infectives to Patients in Need

Our Mission

With a staff of ~70 employees, AiCuris’ head office and research laboratories are located at the Pharma- and Chemistry Park in Wuppertal, Germany, where the company occupies 5.500 square meters, including 3.500 square meters of purpose-built biology and pharmacokinetics facilities. Committed to making the difference, we have more than 15 years of experience in advancing novel approaches. The Company’s first product, Letermovir (Prevymis®), a first-in-class therapy for human cytomegalovirus (HCMV) infections, was successfully out-licensed to Merck & Co., is marketed since 2017 with growing revenues, and has won several prizes for providing a paradigm shift in transplant medicine.

Our path to success

If you or your company are interested in partnering with AiCuris, please contact us.